Home » Regions » Global News » Epirus, Livzon Mabpharm collaborate in China

Epirus, Livzon Mabpharm collaborate in China

Wednesday, October 8, 2014

Epirus Biopharmaceuticals, a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm, a Chinese biotechnology company focused on the development, manufacture and sale of antibody-based drugs.

Epirus and Livzon will work together to develop, manufacture and commercialize up to five biosimilar products. The first collaboration product is Epirus’ Remicade biosimilar BOW015 (infliximab), which recently was approved in India. Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan. Livzon also will serve as the preferred supplier of BOW015 in these territories, following a transfer of Epirus’ SCALE manufacturing platform. Livzon will be responsible for all commercialization activities in its territories.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!